CONFERENCE UPDATE: EADV 2026

Patient voices highlight the persistent disease burden and need for better control of CSU in China

12 Nov 2026

Chronic spontaneous urticaria (CSU) is the most common subtype of chronic urticaria and is characterized by itchy wheals (hives) and/or angioedema for >6 weeks.1 Affecting 1.3% of China’s population, its symptoms can substantially affect patients’ quality of life (QoL), yet the extent of the burden of CSU and patients’ perspectives remain insufficiently understood.1 At the 2026 EADV Congress, Dr. Bin Yang from the Dermatology Hospital, Southern Medical University, China, presented findings from the Urticaria Voices (UV) China study, providing insights into patients’ perspectives on CSU symptoms, comorbidities and the impact of the disease on daily life.1

The UV China study was a non-interventional, cross-sectional online survey conducted between August and October 2025.1 This analysis included Chinese adults aged ≥18 years with self-reported, physician-confirmed CSU.1 Patients were recruited through multiple channels, including online panels, and completed a structured 40-minute survey after providing electronic informed consent.1 Data were analyzed descriptively and reported as means or percentages.1

The analysis included 400 patients with CSU, with a mean age of 35.1 years, of whom 55% were male.1 The mean years since onset was 5.3 years, while the mean years since diagnosis was 5.2 years.1 However, time since diagnosis did not necessarily translate into complete disease control.1 Based on the Urticaria Control Test (UCT), only 14.5% of patients achieved complete control (score=16), while 50.5% were well controlled (score 12-15) and 35.0% were inadequately controlled (score <12).1

The impact of CSU extended well beyond itchy wheals.1 Sleep disruption was the most frequently reported physical symptom during a CSU exacerbation, affecting 70% of patients.1 Nearly half experienced difficulty falling asleep, while three-quarters reported waking during the night.1 Almost half (46%) woke at least 2-3 times per week, and 72.8% reported that lack of sleep affected their daily life, illustrating how symptoms can carry consequences beyond the periods of visible disease activity.1 Fatigue (54%) and flushing (42%) were also commonly reported, adding to the physical burden.1

 

Although only 7% of patients reported ever experiencing angioedema, 85% of this subgroup reported episodes in the preceding 12 months, with a mean of 4.7 episodes.1 Episodes were visible on the face, lips, throat, hands and feet.1 Comorbidities were also common, affecting 60% of patients, with hypertension (14%), sinusitis (13%), and obesity or overweight (11%) being the most common.1

Complete disease control was rated as the most important treatment goal by 80% of patients, receiving an importance rating of approximately 8.5 out of 10.1 Nevertheless, among patients with inadequately controlled CSU, 53.6% described their symptoms as mild, while 22.9% reported moderate symptoms, 1.4% reported severe symptoms, and 22.1% reported no symptoms during the 7 days before survey completion.1

The reported impact of CSU on mental and emotional well-being averaged 3.9 on a scale of 1 to 10, where 10 represented an extremely high negative impact.1 Notably, 56% of patients experienced a moderate impact and 2% a high impact on their mental and emotional well-being.1 Improving mental and emotional well-being was among the leading treatment objectives for 47% of patients, while 46% felt that CSU held them back from reaching their full potential.1 Most patients were treated primarily with second-generation antihistamines (82%), sometimes involving dose adjustments or treatment switching, yet complete control (UCT score=16) remained elusive for many (85%).1

In conclusion, the UV China study highlights the substantial psychosocial burden of CSU among Chinese patients despite diagnosis and treatment.1 Sleep disruption and impaired well-being were common, while complete disease control was achieved by only a minority.1 These findings underscore the need for more effective CSU management strategies and therapies to achieve sustained symptom control, address the physical and psychosocial burden of the disease, and improve overall QoL among patients in China.1

Get access to our exclusive articles.